Reviva Pharmaceuticals Holdings, Inc. Common Stock
0.37
USD
Patrocinado
+0.01
+1.37%
09 ene, 12:50 UTC -5
Apertura
Informes de beneficios de RVPH
Ratio de Sorpresa Positivo
RVPH superó 13 de las últimas 18 estimaciones.
72%
Próximo informe
Fecha del próximo informe
30 mar 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$0.08
Cambio implícito desdeQ3 25(Revenue/ EPS)
--
/
+33.33%
Cambio implícito desdeQ4 24(Revenue/ EPS)
--
/
-46.67%
Reviva Pharmaceuticals Holdings, Inc. Common Stock earnings per share and revenue
On 13 nov 2025, RVPH reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 39.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an aumentar of 33.33% EPS, and aumentar of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26 dic 2025 para Q4 25
Estimar
-$0.49
Actual
-
Sorpresa
-
Preguntas frecuentes
What were Reviva Pharmaceuticals Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Reviva Pharmaceuticals Holdings, Inc. Common Stock reported EPS of -$0.06, beating estimates by 39.46%, and revenue of $0.00, 0% as expectations.
How did the market react to Reviva Pharmaceuticals Holdings, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -7.19%, changed from $0.54 before the earnings release to $0.50 the day after.
When is Reviva Pharmaceuticals Holdings, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30 mar 2026.
What are the forecasts for Reviva Pharmaceuticals Holdings, Inc. Common Stock's next earnings report?
Based on 10
analistas, Reviva Pharmaceuticals Holdings, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.